Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762

Cancer Research

Volumn 72, Issue 4, 2012, Pages 979-989

  Aris, Sheena M ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 7762; CAMPTOTHECIN DERIVATIVE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DNA TOPOISOMERASE INHIBITOR; LMP 400; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CELL CYCLE PROGRESSION; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE MICROSCOPY; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIOXOLES; COLONIC NEOPLASMS; DNA REPLICATION; DRUG SYNERGISM; HT29 CELLS; HUMANS; ISOQUINOLINES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; THIOPHENES; TOPOISOMERASE I INHIBITORS; UREA;

EID: 84857216401     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2579     Document Type: Article

References (50)

1. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17:421-33.
2. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009;109:2894-902.
3. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413. (Pubitemid 32662215)
4. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008;75:1262-71. (Pubitemid 351305209)
5. Pommier Y, Cushman M. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther 2009;8:1008-14.
6. Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, et al. Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol 2006;81:179-229. (Pubitemid 44767505)
7. Kohlhagen G, Paull K, Cushman M, Nagafufuji P, Pommier Y. Protein-linked DNA strand breaks induced by NSC 314622, a non-camptothecin topoisomerase I poison. Mol Pharmacol 1998;54:50-8. (Pubitemid 28337586)
8. Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res 2007;67:10397-405. (Pubitemid 350070815)
9. Ioanoviciu A, Antony S, Pommier Y, Staker BL, Stewart L, Cushman M. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-Enzyme-Inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem 2005;48: 4803-14. (Pubitemid 41033123)
10. Han B, Stockwin LH, Hancock C, Yu SX, Hollingshead MG, Newton DL. Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor. J Proteome Res 2010;9:4016-27.
11. Kinders R, Hollingshead MG, Lawrence S, Ji J, Tabb B, Bonner WM, et al. Development of a validated immunofluorescence assay for gH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin Cancer Res 2010;16:5447-57.
12. Shao R-G, Cao C-X, Shimizu T, O'Connor P, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53. Cancer Res 1997;57:4029-35. (Pubitemid 27427693)
13. Shao RG, Cao CX, Pommier Y. Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells. Acta Pharmacol Sin 2004;25:756-62. (Pubitemid 38736101)
14. Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, et al. A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 2011;67:1225-37.
15. Seiler JA, Conti C, Syed A, Aladjem MI, Pommier Y. The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol 2007;27:5806-18. (Pubitemid 47257835)
16. Pommier Y, Sordet O, Rao A, Zhang H, Kohn KW. Targeting Chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des 2005;11:2855-72. (Pubitemid 41051871)
17. Pommier Y, Weinstein JN, Aladjem MI, Kohn KW. Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin Cancer Res 2006;12:2657-61.
18. Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?Nat Rev Cancer 2007;7:925-36. (Pubitemid 350165855)
19. Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when?Trends Pharmacol Sci 2011;32:308-16.
20. Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv 2011;11:133-40.
21. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298: 1912-34. (Pubitemid 35425239)
22. Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW, Pommier Y. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G (2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 2002;62:5743-8. (Pubitemid 35204730)
23. Jobson AG, Cardellina JH 2nd, Scudiero D, Kondapaka S, Zhang H, Kim H, et al. Identification of a bis-guanylhydrazone [4,40-diacetyldiphenylurea- bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of chk2 kinase. Mol Pharmacol 2007;72:876-84. (Pubitemid 47481411)
24. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010;108:73-112.
25. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448-59. (Pubitemid 30421838)
26. Peddibhotla S, Lam MH, Gonzalez-Rimbau M, Rosen JM. The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis. Proc Natl Acad Sci U S A 2009;106:5159-64.
27. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010;40:179-204.
28. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008;7:2955-66.
29. McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y, et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010;9:995-1004.
30. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010;16:2076-84.
31. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010;70:4972-81.
32. Xu H, Cheung IY, Wei XX, Tran H, Gao X, Cheung NK. Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G(1) checkpoint- defective neuroblastoma. Int J Cancer 2011;129:1953-62.
33. Takemura H, Rao VA, Sordet O, Furuta T, Miao ZH, Meng L, et al. Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia Mutated in Colorectal carcinoma cells in response to replication- dependent DNA double strand breaks. J Biol Chem 2006;281:30814-23. (Pubitemid 44582136)
34. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 2007;13:591-602. (Pubitemid 46225366)
35. Conti C, Caburet S, Bensimon A. Targeting the molecular mechanism of DNA replication. Drug Discov Today 2001;6:786-92. (Pubitemid 32722221)
36. Conti C, Seiler J, Pommier Y. The mammalian dna replication elongation checkpoint: implication of Chk1 and relationship with origin firing as determined by single dna molecule and single cell analyses. Cell Cycle 2007;6:2760-7. (Pubitemid 350277167)
37. Courbet S, Gay S, Arnoult N, Wronka G, Anglana M, Brison O, et al. Replication fork movement sets chromatin loop size and origin choice in mammalian cells. Nature 2008;455:557-60.
38. Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, et al. Destabilization of CHK2 by a missense mutation associated with Li- Fraumeni syndrome. Cancer Res 2001;61:8062-7. (Pubitemid 33091590)
39. Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 2004;18:3041-54. (Pubitemid 39658173)
40. Jallepalli PV, Lengauer C, Vogelstein B, Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 2003;278:20475-9. (Pubitemid 36806343)
41. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989;49:5016-22. (Pubitemid 19239335)
42. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994;37:40-6. (Pubitemid 24058811)
43. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002;99:15387-92. (Pubitemid 35403944)
44. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802. (Pubitemid 44450467)
45. Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, et al. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001;154:913-23. (Pubitemid 34286172)
46. Falck J, Petrini JH, Williams BR, Lukas J, Bartek J. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 2002;30:290-4.
47. Le Breton C, Hennion M, Arimondo PB, Hyrien O. Replication-fork stalling and processing at a single psoralen interstrand crosslink in Xenopus egg extracts. PLoS One 2011;6:e18554.
48. Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J Antibiot (Tokyo) 1987;40:1782-4. (Pubitemid 18023359)
49. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002;21:1727-38. (Pubitemid 34259036)
50. Niida H, Murata K, Shimada M, Ogawa K, Ohta K, Suzuki K, et al. Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo. EMBO J 2010;29:3558-70.